Biotech | August 06, 2024
Lupin completes successful Phase 3 trials for Lucentis biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Campaign launched to spread awareness regarding dengue prevention and control
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
The facility is a part of Lupin Manufacturing Solutions
This product will be manufactured at Lupin’s Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
